Literature DB >> 24735750

The past, present and future of breast cancer research in China.

Wei Hong1, Erdan Dong2.   

Abstract

The incidence of breast cancer has increased rapidly in recent years and has now become the most common cancer in women in major cities of China. Here, we reviewed the history and progress of breast cancer research in China, including achievements that Chinese scientists have made in basic, translational and clinical research. Moreover, we evaluated the contributions of National Natural Science Foundation of China (NSFC) in the field of breast cancer research. The number of grants funded by the NSFC for breast cancer has tripled from 87 to 274 in the past 5years, and this resulted in a dramatic increase in breast cancer publications. Despite this great progress, policy makers are continuously taking efforts to guarantee the transparency of grant competition and the effective use of NSFC finding.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; China; Funding; Research

Mesh:

Year:  2014        PMID: 24735750     DOI: 10.1016/j.canlet.2014.04.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  32 in total

1.  The long non-coding RNA SUMO1P3 facilitates breast cancer progression by negatively regulating miR-320a.

Authors:  Jie Liu; Zhiwang Song; Chan Feng; Yonglin Lu; Yu Zhou; Yun Lin; Chunyan Dong
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Panli Li; Xiuying Wang; Chongrui Xu; Cheng Liu; Chaojie Zheng; Michael J Fulham; Dagan Feng; Lisheng Wang; Shaoli Song; Gang Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-25       Impact factor: 9.236

3.  Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A.

Authors:  Wanjun Li; Guoyin Li; Zhigang Fan; Tao Liu
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

4.  SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients.

Authors:  Guo-Dong Song; Yu Sun; Hong Shen; Wei Li
Journal:  Tumour Biol       Date:  2015-01-16

5.  Bishonokiol A inhibits breast cancer cell invasion and migration by suppressing hypoxia inducible factor-1α.

Authors:  Hong-Mei Li; Jian Miao; Meilin Zhu; Meijia Gao; Yiqun Dai; Qiang Huo; Tao Ma; Cheng-Zhu Wu
Journal:  J Bioenerg Biomembr       Date:  2019-05-06       Impact factor: 2.945

6.  PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer.

Authors:  Jufang Guo; Xuelian Du; Chaolin Li
Journal:  Biomed Res Int       Date:  2022-04-30       Impact factor: 3.246

7.  Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2.

Authors:  Yi Guo; Yuning Zhang; Xunjun Yang; Panpan Lu; Xijuan Yan; Fanglan Xiao; Huaibin Zhou; Chaowei Wen; Mengru Shi; Jianxin Lu; Qing H Meng
Journal:  Cancer Biol Ther       Date:  2015-11-30       Impact factor: 4.742

8.  Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition.

Authors:  Erjie Xia; Yanyan Shen; Adheesh Bhandari; Xiaofen Zhou; Yinghao Wang; Fan Yang; Ouchen Wang
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

9.  Ankle loading ameliorates bone loss from breast cancer-associated bone metastasis.

Authors:  Shuang Yang; Hong Liu; Lei Zhu; Xinle Li; Daquan Liu; Xiaomeng Song; Hiroki Yokota; Ping Zhang
Journal:  FASEB J       Date:  2019-07-02       Impact factor: 5.834

10.  MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1.

Authors:  Yancheng Lin; Allan Yi Liu; Chuannan Fan; Hong Zheng; Yuan Li; Chuankai Zhang; Shasha Wu; Donghong Yu; Zhengjie Huang; Fan Liu; Qi Luo; Chaoyong James Yang; Gaoliang Ouyang
Journal:  Sci Rep       Date:  2015-04-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.